Related Experiment Video
Updated: Jan 26, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
Identification of a peptide antagonist of the FGF1-FGFR1 signaling axis by phage display selection
Magdalena Lipok1,2, Anna Szlachcic1,2, Kinga Kindela1
1Department of Protein Engineering, Faculty of Biotechnology, University of Wroclaw, Poland.
Abstract:
Overexpression of fibroblast growth factor receptor 1 (FGFR1) is a common aberration in lung and breast cancers and has necessitated the design of drugs targeting FGFR1-dependent downstream signaling and FGFR1 ligand binding. To date, the major group of drugs being developed for treatment of FGFR1-dependent cancers are small-molecule tyrosine kinase inhibitors; however, the limited specificity of these drugs has led to increasing attempts to design molecules targeting the extracellular domain of FGFR1. Here, we used the phage display technique to select cyclic peptides F8 (ACSLNHTVNC) and G10 (ACSAKTTSAC) as binders of the fibroblast growth factor 1 (FGF1)-FGFR1 interface. ELISA and in vitro cell assays were performed to reveal that cyclic peptide F8 is more effective in preventing the FGF1-FGFR1 interaction, and also decreases FGF1-induced proliferation of BA/F3 FGFR1c cells by over 40%. Such an effect was not observed for BA/F3 cells lacking FGFR1. Therefore, cyclic peptide F8 can act as a FGF1-FGFR1 interaction antagonist, and may be suitable for further development for potential use in therapies against FGFR1-expressing cancer cells.
Insights
Researchers identified cyclic peptide F8 as a potent antagonist of fibroblast growth factor 1 (FGF1)-fibroblast growth factor receptor 1 (FGFR1) interaction. This peptide shows promise for developing new therapies against FGFR1-expressing cancers.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Fibroblast growth factor receptor 1 (FGFR1) overexpression is prevalent in lung and breast cancers.
- Current FGFR1-targeted drugs (small-molecule tyrosine kinase inhibitors) have limited specificity.
- There is a need for novel therapeutics targeting the extracellular domain of FGFR1.
Purpose of the Study:
- To identify novel molecules targeting the FGF1-FGFR1 interaction interface.
- To evaluate the potential of cyclic peptides as FGFR1 antagonists for cancer therapy.
Main Methods:
- Phage display technique was employed to select cyclic peptides.
- Enzyme-linked immunosorbent assay (ELISA) and in vitro cell assays were utilized.
- BA/F3 cells with and without FGFR1 expression were used for validation.
Main Results:
- Cyclic peptides F8 and G10 were identified as binders of the FGF1-FGFR1 interface.
- Cyclic peptide F8 demonstrated superior efficacy in blocking FGF1-FGFR1 interaction.
- Peptide F8 significantly inhibited FGF1-induced proliferation of FGFR1-expressing cells by over 40%.
Conclusions:
- Cyclic peptide F8 acts as a functional antagonist of the FGF1-FGFR1 interaction.
- Peptide F8 holds potential for the development of targeted therapies against FGFR1-driven cancers.
Related Concept Videos
Peptide Identification Using Tandem Mass Spectrometry
This technique helps gather information regarding the protein from which the peptide was obtained and to study the peptides’ amino acid sequence. Identifying peptides from a complex mixture is an important component of the growing field of...
Hypothalamic-Pituitary Axis
Peptide Bonds
Perpendicular-Axis Theorem
Consider a circular disc of mass M and radius R lying along an x-y plane. The origin lies at the center of the disc, and the z-axis is perpendicular to the disc's plane. All three axes coincide at the disc's center. The moment of inertia of this...
Parallel-axis Theorem
Bacterial Signaling

